China’s first base-editing treatment for a sickle cell patient remains free of vaso-occlusive crises for 15 months

▤ Summary

CorrectSequence Therapeutics announced that China’s first base-editing treatment for sickle cell disease has kept a patient free of vaso-occlusive crises for more than 15 months. The company says the patient also achieved sustained recovery from anemia and met the primary efficacy endpoint. It highlights favorable safety and efficacy data from its CS-206 autologous cell therapy. The article also notes that the company is recruiting more patients and advancing both CS-206 and CS-101 toward clinical and commercialization milestones.

▦ Linked Companies